StockNews.AI
ALKS
StockNews.AI
124 days

Alkermes to Report First Quarter Financial Results on May 1, 2025

1. Alkermes will discuss Q1 financial results on May 1, 2025. 2. The company focuses on neuroscience-based innovative medicines. 3. ALKS has commercial products for addiction and several mental health conditions. 4. Its pipeline includes candidates for narcolepsy and hypersomnia. 5. The upcoming event highlights Alkermes' financial health and future prospects.

Earnings
-0.07%Current Return
VS
+0.01%S&P 500
$27.0204/17 04:07 PM EDTEvent Start
$2704/18 10:23 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming call could reflect positive developments in product pipeline and revenue. Historically, financial calls with positive outcomes have led to stock increases.

How important is it?

The Q1 results can significantly influence investor sentiment and stock valuation. Positive earnings reports typically lead to enhanced stock prices.

Why Short Term?

Recent financial performances have short-term impacts due to investor sentiment. Earnings announcements often lead to volatility and can quickly influence trading behavior.

Related Companies

AMGNBIIBJNJ
, /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plc  Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com. Alkermes Contact: Jamie Constantine Investor Relations +1 781 873 2402 SOURCE Alkermes plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News